Climb Bio announces CLYM116 Phase 1 data in IgA nephropathy
Climb Bio says CLYM116 Phase 1 data shows prolonged half-life and APRIL suppression supporting every-12-week dosing in IgA nephropathy.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.